Time to Jump In? Raymond James Is Bullish on These 2 Stocks
TipRanks (Thu, 23-Jul 5:57 AM ET)
Alpha Cognition’s RESOLVE Study: Fresh Real-World Data on Zunveyl in Alzheimer’s Care
TipRanks (Mon, 20-Jul 12:30 PM ET)
Business Wire (Fri, 10-Jul 8:30 AM ET)
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Business Wire (Tue, 23-Jun 8:30 AM ET)
Business Wire (Tue, 16-Jun 8:30 AM ET)
Business Wire (Tue, 9-Jun 8:00 AM ET)
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
Business Wire (Thu, 14-May 4:15 PM ET)
Business Wire (Tue, 28-Apr 4:30 PM ET)
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Business Wire (Mon, 27-Apr 8:00 AM ET)
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Alpha Cognition trades on the NASDAQ stock market under the symbol ACOG.
As of July 23, 2026, ACOG stock price climbed to $7.93 with 45,275 million shares trading.
ACOG has a beta of 2.50, meaning it tends to be more sensitive to market movements. ACOG has a correlation of 0.19 to the broad based SPY ETF.
ACOG has a market cap of $172.67 million. This is considered a Micro Cap stock.
Last quarter Alpha Cognition reported $4 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.08.
ACOG has underperformed the market in the last year with a price return of -19.1% while the SPY ETF gained +18.7%. However, in the short term, ACOG had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.4% vs +4.2% return in SPY. But in the last 2 weeks, ACOG shares have been beat by the market, returning -6.7% compared to an SPY return of -0.8%.
ACOG support price is $7.51 and resistance is $8.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOG shares will trade within this expected range on the day.
